Cargando…
A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial
Despite the progress that has been made in other forms of cancer therapy, Provenge® (Sipuleucel-T) is the only FDA-approved vaccine for the treatment of cancer. To understand the current landscape of therapeutic oncology vaccines we performed a quantitative analysis of phase 2 and phase 3 therapeuti...
Autores principales: | Tan, Amabel CL, Goubier, Anne, Kohrt, Holbrook E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647658/ https://www.ncbi.nlm.nih.gov/pubmed/26579225 http://dx.doi.org/10.1186/s40425-015-0093-x |
Ejemplares similares
-
Understanding CD8(+) T-cell responses toward the native and alternate HLA-A*02:01-restricted WT1 epitope
por: Nguyen, Thi HO, et al.
Publicado: (2017) -
Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials
por: Calzetta, Luigino, et al.
Publicado: (2021) -
Quantitative phase spectroscopy
por: Rinehart, Matthew, et al.
Publicado: (2012) -
Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia
por: Daayana, S, et al.
Publicado: (2010) -
HIV therapeutic vaccine enhances non-exhausted CD4(+) T cells in a randomised phase 2 trial
por: Vieillard, Vincent, et al.
Publicado: (2019)